Pre-Formulation Development of Lamivudine 300 mg and Tenofovir Disoproxil Fumarate (TDF) 300 mg Fixed Dose Combination Tablets

Journals Menu

Follow SCIRP

ISSN Print: 2157-9423
ISSN Online: 2157-9431
www.scirp.org/journal/pp
E-mail: pp@scirp.org

"Pre-Formulation Development of Lamivudine 300 mg and Tenofovir Disoproxil Fumarate (TDF) 300 mg Fixed Dose Combination Tablets"
written by Prosper Tibalinda, Dickson Pius, Raphael Shedafa, Nelson Masota, Mary Temu, Eliangiringa Kaale,
published by Pharmacology & Pharmacy, Vol.7 No.7, 2016

has been cited by the following article(s):

[1]	Designand Evaluationof Fixed-Dose Combination of Bi-Layer Tablets of Dolutegravir, Lamivudine and Tenofovir Disoproxil Fumarate Tablets 50 Mg/300 Mg/300 Mg
	Asian Journal of Pharmaceutical …, 2022

[2]	FORMULATION AND DEVELOPMENT OF COLON TARGETED MATRIX TABLET OF TENOFOVIR DF
	2018

Follow SCIRP

[1]	Current Trends in the Identification and Development of Antimicrobial Agents 2023 DOI:10.2174/9789815080056123020006